Clinical Efficacy and Safety of Immunotherapy Retreatment in Metastatic Cervical Cancer: A Retrospective Study
Guiling Li,1,* Mingxia Cheng,1,* Kai Hong,2,* Yao Jiang1 1Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China; 2Department of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Huazh...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2023-03-01
|
| Series: | OncoTargets and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/clinical-efficacy-and-safety-of-immunotherapy-retreatment-in-metastati-peer-reviewed-fulltext-article-OTT |
| _version_ | 1811158615723081728 |
|---|---|
| author | Li G Cheng M Hong K Jiang Y |
| author_facet | Li G Cheng M Hong K Jiang Y |
| author_sort | Li G |
| collection | DOAJ |
| description | Guiling Li,1,* Mingxia Cheng,1,* Kai Hong,2,* Yao Jiang1 1Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China; 2Department of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yao Jiang, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China, Tel +86 13797011369, Fax +86-27-85873062, Email asdfjkl19@hotmail.comPurpose: Metastatic cervical cancer has a poor prognosis, and treatment options are limited. Immunotherapy has been used to achieve disease control in patients with cervical cancer; however, the efficacy of immunotherapy retreatment after disease progression is unclear. This study aimed to explore the efficacy and safety of immunotherapy retreatment in metastatic cervical cancer.Patients and methods: We retrospectively reviewed the clinical data of patients with metastatic cervical cancer who underwent immunotherapy retreatment after disease progression following previous immunotherapy from June 2019 to April 2021.Results: Fifteen patients were included in this study. All patients received combination immunotherapy retreatment consisting of camrelizumab, nab-paclitaxel, and apatinib. Four (26.7%) patients achieved partial response while three (20.0%) achieved stable disease. The objective response rate and disease control rate were 26.7% and 46.7%, respectively. The median progression-free survival and overall survival were 3.0 (95% confidence interval: 1.0– 5.0) and 8.0 (95% confidence interval: 3.4– 12.6) months, respectively. None of the patients discontinued treatment because of intolerable toxicity.Conclusion: Our findings suggest that the triplet combination immunotherapy retreatment could be a therapeutic option for patients with metastatic cervical cancer who failed initial immunotherapy.Keywords: apatinib, camrelizumab, disease progression, nab-paclitaxel, survival, toxicity |
| first_indexed | 2024-04-10T05:27:07Z |
| format | Article |
| id | doaj.art-966cbc9c77374b709a8973ea8309ce08 |
| institution | Directory Open Access Journal |
| issn | 1178-6930 |
| language | English |
| last_indexed | 2024-04-10T05:27:07Z |
| publishDate | 2023-03-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | OncoTargets and Therapy |
| spelling | doaj.art-966cbc9c77374b709a8973ea8309ce082023-03-07T18:15:45ZengDove Medical PressOncoTargets and Therapy1178-69302023-03-01Volume 1615716382053Clinical Efficacy and Safety of Immunotherapy Retreatment in Metastatic Cervical Cancer: A Retrospective StudyLi GCheng MHong KJiang YGuiling Li,1,* Mingxia Cheng,1,* Kai Hong,2,* Yao Jiang1 1Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China; 2Department of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yao Jiang, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China, Tel +86 13797011369, Fax +86-27-85873062, Email asdfjkl19@hotmail.comPurpose: Metastatic cervical cancer has a poor prognosis, and treatment options are limited. Immunotherapy has been used to achieve disease control in patients with cervical cancer; however, the efficacy of immunotherapy retreatment after disease progression is unclear. This study aimed to explore the efficacy and safety of immunotherapy retreatment in metastatic cervical cancer.Patients and methods: We retrospectively reviewed the clinical data of patients with metastatic cervical cancer who underwent immunotherapy retreatment after disease progression following previous immunotherapy from June 2019 to April 2021.Results: Fifteen patients were included in this study. All patients received combination immunotherapy retreatment consisting of camrelizumab, nab-paclitaxel, and apatinib. Four (26.7%) patients achieved partial response while three (20.0%) achieved stable disease. The objective response rate and disease control rate were 26.7% and 46.7%, respectively. The median progression-free survival and overall survival were 3.0 (95% confidence interval: 1.0– 5.0) and 8.0 (95% confidence interval: 3.4– 12.6) months, respectively. None of the patients discontinued treatment because of intolerable toxicity.Conclusion: Our findings suggest that the triplet combination immunotherapy retreatment could be a therapeutic option for patients with metastatic cervical cancer who failed initial immunotherapy.Keywords: apatinib, camrelizumab, disease progression, nab-paclitaxel, survival, toxicityhttps://www.dovepress.com/clinical-efficacy-and-safety-of-immunotherapy-retreatment-in-metastati-peer-reviewed-fulltext-article-OTTapatinibcamrelizumabdisease progressionnab-paclitaxelsurvivaltoxicity |
| spellingShingle | Li G Cheng M Hong K Jiang Y Clinical Efficacy and Safety of Immunotherapy Retreatment in Metastatic Cervical Cancer: A Retrospective Study OncoTargets and Therapy apatinib camrelizumab disease progression nab-paclitaxel survival toxicity |
| title | Clinical Efficacy and Safety of Immunotherapy Retreatment in Metastatic Cervical Cancer: A Retrospective Study |
| title_full | Clinical Efficacy and Safety of Immunotherapy Retreatment in Metastatic Cervical Cancer: A Retrospective Study |
| title_fullStr | Clinical Efficacy and Safety of Immunotherapy Retreatment in Metastatic Cervical Cancer: A Retrospective Study |
| title_full_unstemmed | Clinical Efficacy and Safety of Immunotherapy Retreatment in Metastatic Cervical Cancer: A Retrospective Study |
| title_short | Clinical Efficacy and Safety of Immunotherapy Retreatment in Metastatic Cervical Cancer: A Retrospective Study |
| title_sort | clinical efficacy and safety of immunotherapy retreatment in metastatic cervical cancer a retrospective study |
| topic | apatinib camrelizumab disease progression nab-paclitaxel survival toxicity |
| url | https://www.dovepress.com/clinical-efficacy-and-safety-of-immunotherapy-retreatment-in-metastati-peer-reviewed-fulltext-article-OTT |
| work_keys_str_mv | AT lig clinicalefficacyandsafetyofimmunotherapyretreatmentinmetastaticcervicalcanceraretrospectivestudy AT chengm clinicalefficacyandsafetyofimmunotherapyretreatmentinmetastaticcervicalcanceraretrospectivestudy AT hongk clinicalefficacyandsafetyofimmunotherapyretreatmentinmetastaticcervicalcanceraretrospectivestudy AT jiangy clinicalefficacyandsafetyofimmunotherapyretreatmentinmetastaticcervicalcanceraretrospectivestudy |